Shawn DeFrees
Nessuna posizione attualmente
Profilo
Shawn DeFrees has been Vice President-Research & Development of Neose Technologies, Inc. since June 2003.
Previously, he served as Senior Director-Research and Development from July 1999 to July 2003.
Dr. DeFrees was Director-Discovery Chemistry for Cytel Corporation from 1991 to 1999 and a Staff Scientist-Cardiovascular of Schering-Plough Corporation from 1988 to 1991.
He received a BS degree in Biochemistry from Albright College and a PhD in Synthetic Medicinal Chemistry from Purdue University.
Precedenti posizioni note di Shawn DeFrees
Società | Posizione | Fine |
---|---|---|
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Direttore Tecnico/Scientifico/R&S | 08/07/2010 |
Cytel Corp. | Direttore Tecnico/Scientifico/R&S | 01/01/1999 |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Corporate Officer/Principal | 01/01/1991 |
Formazione di Shawn DeFrees
Albright College | Undergraduate Degree |
Purdue University | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 3 |
---|---|
Neose Technologies, Inc.
Neose Technologies, Inc. Pharmaceuticals: MajorHealth Technology The Group's principal activity is to develop proprietary drugs, focusing primarily on therapeutic proteins. Its technologies to develop proprietary versions of protein drugs with proven safety and efficacy and to improve the therapeutic profiles of proteins being developed. Its proprietary drug development portfolio currently consists of two therapeutic protein candidates.GlycoPEG-EPO (NE-180) is a long-acting version of erythropoietin (EPO) produced in insect cells. EPO is prescribed to stimulate production of red blood cells, and it gives treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure. Its second proprietary protein, GlycoPEG-GCSF, is a long-acting version of granulocyte colony stimulating factor G-CSF and it is prescribed to stimulate production of neutrophils (a type of white blood cell). Its trademarks are NEOSE, GlycoPEGylation and GlycoConjugation. It operates predominantly in the domestic market. | Health Technology |
Cytel Corp. | |
Schering-Plough Corp.
Schering-Plough Corp. Pharmaceuticals: MajorHealth Technology Schering Plough Corp. manufactures and sells pharmaceuticals, consumer and animal health care products. The firm discovers, develops, manufactures and markets advanced drug therapies. The company is headquartered in Kenilworth, NJ. | Health Technology |
- Borsa valori
- Insiders
- Shawn DeFrees